Keen2 bracelet to increase awareness and reduce hair-pulling in adults with trichotillomania

Technology Assisted Treatment for Trichotillomania: Open Trial

Not applicable Interventional HabitAware Inc. · NCT07224126

This study will try a Keen2 wearable bracelet to help adults with trichotillomania notice and reduce hair-pulling by detecting episodes and sending personalized vibration alerts.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment10 (estimated)
Ages18 Years and up
SexAll
SponsorHabitAware Inc. Industry-sponsored
Locations1 site (Kent, Ohio)
Trial IDNCT07224126 on ClinicalTrials.gov

What this trial studies

This open-label, single-arm feasibility study gives adults with trichotillomania a Keen2 bracelet and companion app for eight weeks to test a digital awareness intervention. During the first four weeks participants wear the device and log contextual details after each detected pulling episode. In weeks five through eight the system uses those data to deliver individualized predictive vibration alerts tied to stimulus control, competing responses, and coping strategies. Primary outcomes include usability, adherence, and change in self-reported pulling severity (MGH-HPS) from baseline to week 8 with a week 12 follow-up.

Who should consider this trial

Good fit: Adults (18+) with a diagnosis of trichotillomania who speak English, own an iPhone, have internet access, are not changing TTM treatments (or have been stable for 6+ weeks), and can identify an emergency contact are ideal candidates.

Not a fit: People with active suicidal or homicidal ideation, unstable psychiatric conditions, those who do not use an iPhone, or those currently changing pharmacologic or psychosocial TTM treatments are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, the bracelet could help people with trichotillomania become more aware of triggers and reduce pulling by providing timely reminders and coping prompts.

How similar studies have performed: Small feasibility and pilot studies of wearable awareness devices for body-focused repetitive behaviors have shown promise for improving awareness, but randomized controlled evidence remains limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18 years of age (criterion 1a) with a diagnosis of TTM (criterion 1b)
* Must reportEnglish as their primary language (criterion 2)
* Report no current pharmacological or psychosocial intervention targeting TTM symptoms OR a6-week course of either intervention modality without change in frequency,intensity, or dosage (criterion 3)
* Reliable and consistent access to the internet and/or mobile device permitting the participant to meet withsomeone virtually for 90 min.
* Must report owning/access to a mobilephone running on Apple's operating system (iOS)
* Identifies a support person that is able to be contacted is an emergency arises.
* Agrees to allow the Kent State research team to share home address, mobile number, andalternate number/email with HabitAware, Inc., for purposes of mailing Keen2device and setting up Keen2 system.

Exclusion Criteria:

* Current suicidal/homicidal ideation, intent, or plan
* a diagnosis of another psychiatric condition that may impeded a participant's ability to fully utilize the app (e.g., psychotic disorder, major depressive disorder)

Where this trial is running

Kent, Ohio

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Trichotillomaniahair pulling disorderBFRBBody-Focused Repetitive Behaviortrichotillomaniatrich
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.